Recent Updates
Recently added Catalysts

Tourmaline Bio, Inc.

TRMLFDA catalysts, PDUFA dates & pipeline intelligence
$47.98
▲ 0 · 0%

Last traded Oct 27, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TRML financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $11.5652W HIGH $48.27
Volume
783.73 K
Value Traded
37.61 M
Short % Float
5.51%
Days to Cover
1.8
+0.17%Week
+0.52%1 Month
+111.27%3 Month
+201.38%6 Month
-72.19%5 Year
-72.19%All Time

Cash Data

Unlock TRML cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.23 B
EPS (TTM)
-3.44
P/E Ratio
-
Ent. Value
993.63 M
Total Shares
25.69 M
Float Shares
14.68 M
Insiders
36.27%
Institutions
72.70%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TRML catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TRML Catalyst Timeline

Dated clinical, regulatory and corporate events for Tourmaline Bio, Inc.

Unlock the full TRML catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TRML actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-06-30TOUR006 Phase 2 data readout Phase 2
Unlock 1 more TRML historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 2 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
TOUR006 Small moleculeNCT06088979Thyroid Eye DiseasePhase 2 ACTIVE NOT_RECRUITING 79Sep 1, 2027
TOUR006 Small moleculeCompletedNCT06362759Chronic Kidney DiseasesPhase 2 COMPLETED 143Dec 4, 2025
Unlock the TRML pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TRML program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
pacibekitug chronic kidney diseasePhase 22025-08-31hs CRP reduction: >85%; statistical significance: p<0.0001; fibrinogen reduction: statistically significant in all three pacibekitug dose arms; lipoprotein a reduction: statistically significant in the 50mg quarterly and 15mg monthly armsRead MoreTourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology CongressRead More
Scroll for more · summaries link to the source press release
Unlock every TRML trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TRML insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Robinson Ryan F.Officer (CFO)Option 14,366 14,366 held$13.92 10/22/2025
Unlock the full TRML insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in TRML

Fund % of Portfolio Current MV Shares Owned Activity
Avoro Capital Advisors LLC 1.6 % (128.6 %) 122.23 M 2.56 M
Unlock every fund holding TRML
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TRML
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TRML ownership
Insider and institutional ownership, quarter by quarter.

TRML Short Interest

Shares sold short, counted twice a month.

5.51%
Short % of Float
of tradable shares sold short
809.0K
Shares Sold Short
-17.7% vs prior count
1.8 Low
Days to Cover
trading days of normal volume to buy every short share back
447.5K
Avg Daily Volume
the average used for days to cover
Unlock TRML short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock TRML option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TRML option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TRML options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TRML ranks across every disease it competes in

Competitive Position is a premium feature
See how TRML ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TRML News

About Tourmaline Bio, Inc.

BIOPHARMAWATCH ELITE PLUS
Trade the next TRML catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime